Lower Manhattan-based Metsera is one of the latest drug startups to throw its hat into the ring with the pharma giants ...

After a slow week last week, big rounds saw a good rebound with seven startups raising $100 million or more. While food ...

AstraZeneca and Amgen announced that a Phase 3 trial of Tezspire (tezepelumab) showed a statistically significant and ...

Metsera has brought in over $500m in funding in just seven months as it looks to enter the competitive weight loss arena.

New York-based Metsera, a biopharma developing medicines for obesity and metabolic diseases, has closed a $215 million Series ...

The sizeable new round follows the announcement of phase 1 data for its lead asset MET-097i in September and, according to ...

Kebilidi is the first gene therapy approved by the FDA for administration directly into the brain, given via a cannula during ...

with a readout expected before the end of the year. Other players include Metsera, a newly emerged weight loss biotech that ...

To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Metsera, already a well-funded ...

Despite crowding in the next-gen weight loss space, Metsera has raised over $500 million since its April launch, indicating a ...

Just sev­en months af­ter un­veil­ing with $290 mil­lion, obe­si­ty biotech Met­sera is back with an­oth­er $215 mil­lion.

Metsera is riding the wave of continued enthusiasm for GLP-1 drugs and its own early-stage data to bring in a hefty $215 ...